Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yujin Hoshida

Showing results (11-20 of 263) with videos related to

Pageof 27
Sort By:
Journal of Hepatology|May 28, 2011
Depicting the role of TP53 in hepatocellular carcinoma progressionAugusto Villanueva, Yujin Hoshida
Hepatic Oncology|October 11, 2018
Molecular heterogeneity in hepatocellular carcinomaShijia Zhu, Yujin Hoshida
Clinical Liver Disease|July 28, 2015
Personalized management of hepatocellular carcinoma based on molecular information: future prospectsNicolas Goossens, Yujin Hoshida
Clinical and Molecular Hepatology|September 1, 2024
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"Hiroaki Kanzaki, Yujin Hoshida
Trends in Molecular Medicine|July 14, 2020
Viral Exposure Signature Associated with Liver Cancer RiskNaoto Fujiwara, Yujin Hoshida
Gastroenterology|January 20, 2016
Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?Nicolas Goossens, Yujin Hoshida
Hepatology (Baltimore, Md.)|March 23, 2013
Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinomaManjeet Deshmukh, Yujin Hoshida
Viruses|May 18, 2019
Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular CarcinomaThomas F Baumert, Yujin Hoshida
Annals of Surgical Oncology|June 26, 2013
Prognostic gene signatures for hepatocellular carcinoma: what are we measuring?Kenneth K Tanabe, Yujin Hoshida
The New England Journal of Medicine|March 14, 2009
Prolonged therapy for hepatitis C with low-dose peginterferonYujin Hoshida, Todd R Golub
Pageof 27

Showing results (11-20 of 263) with videos related to

Sort By:
Pageof 27
Journal of Hepatology|May 28, 2011
Depicting the role of TP53 in hepatocellular carcinoma progressionAugusto Villanueva, Yujin Hoshida
Hepatic Oncology|October 11, 2018
Molecular heterogeneity in hepatocellular carcinomaShijia Zhu, Yujin Hoshida
Clinical Liver Disease|July 28, 2015
Personalized management of hepatocellular carcinoma based on molecular information: future prospectsNicolas Goossens, Yujin Hoshida
Clinical and Molecular Hepatology|September 1, 2024
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"Hiroaki Kanzaki, Yujin Hoshida
Trends in Molecular Medicine|July 14, 2020
Viral Exposure Signature Associated with Liver Cancer RiskNaoto Fujiwara, Yujin Hoshida
Gastroenterology|January 20, 2016
Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?Nicolas Goossens, Yujin Hoshida
Hepatology (Baltimore, Md.)|March 23, 2013
Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinomaManjeet Deshmukh, Yujin Hoshida
Viruses|May 18, 2019
Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular CarcinomaThomas F Baumert, Yujin Hoshida
Annals of Surgical Oncology|June 26, 2013
Prognostic gene signatures for hepatocellular carcinoma: what are we measuring?Kenneth K Tanabe, Yujin Hoshida
The New England Journal of Medicine|March 14, 2009
Prolonged therapy for hepatitis C with low-dose peginterferonYujin Hoshida, Todd R Golub
Pageof 27